LINDAHL RICHARD S has filed 25 insider transactions across 2 companies since April 2023.
Most recent transaction: a transaction of 20321 shares of Emergent BioSolutions Inc. ($EBS) on February 25, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 25, 2026 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | H | Employee Stock Option (Right to buy) | 20321 | $0.00 | 0.0000 | 56,700,000 | 100.00% | 0.04% |
| May 7, 2025 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | H | Employee Stock Option (Right to buy) | 19963 | $0.00 | 0.0000 | 53,000,000 | 100.00% | 0.04% |
| March 5, 2026 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 23650 | $8.44 | 215,367.0000 | 56,700,000 | 9.89% | 0.04% |
| March 3, 2026 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | A | Employee Stock Option (Right to buy) | 72856 | $0.00 | 557,346.0000 | 56,700,000 | 15.04% | 0.13% |
| March 1, 2026 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 683 | $8.15 | 239,017.0000 | 56,700,000 | 0.28% | 0.00% |
| Feb. 6, 2026 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | D | Common Stock | 46155 | $10.92 | 245,342.0000 | 56,700,000 | 15.83% | 0.08% |
| Feb. 6, 2026 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 5642 | $10.92 | 239,700.0000 | 56,700,000 | 2.30% | 0.01% |
| Jan. 2, 2026 | Compass Therapeutics, Inc. | $CMPX | LINDAHL RICHARD S | Director | A | Stock Option (Right to Buy) | 90000 | $0.00 | 90,000.0000 | 177,862,102 | 9999.99% | 0.05% |
| Oct. 15, 2025 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 4995 | $9.60 | 291,497.0000 | 56,700,000 | 1.68% | 0.01% |
| June 8, 2025 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 2733 | $6.63 | 296,492.0000 | 53,000,000 | 0.91% | 0.01% |
| March 6, 2025 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | A | Common Stock | 146888 | $0.00 | 299,225.0000 | 53,000,000 | 96.42% | 0.28% |
| March 6, 2025 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | A | Employee Stock Options (Right to Buy) | 178546 | $0.00 | 484,490.0000 | 53,000,000 | 58.36% | 0.34% |
| March 1, 2025 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 683 | $7.48 | 152,337.0000 | 53,000,000 | 0.45% | 0.00% |
| Feb. 12, 2025 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | D | Common Stock | 16916 | $0.00 | 154,093.0000 | 53,000,000 | 9.89% | 0.03% |
| Feb. 28, 2025 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 1073 | $7.48 | 153,020.0000 | 53,000,000 | 0.70% | 0.00% |
| Feb. 11, 2025 | Compass Therapeutics, Inc. | $CMPX | LINDAHL RICHARD S | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| Oct. 15, 2024 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | A | Common Stock | 15000 | $0.00 | 171,009.0000 | 55,600,000 | 9.61% | 0.03% |
| June 8, 2024 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 2733 | $6.19 | 156,009.0000 | 51,200,000 | 1.72% | 0.01% |
| March 13, 2024 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | A | Employee Stock Options (Right to Buy) | 125000 | $0.00 | 305,944.0000 | 51,200,000 | 69.08% | 0.24% |
| March 1, 2024 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 684 | $3.39 | 158,742.0000 | 51,200,000 | 0.43% | 0.00% |
| Feb. 29, 2024 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 9037 | $3.23 | 159,426.0000 | 51,200,000 | 5.36% | 0.02% |
| Feb. 23, 2024 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | Common Stock | 517 | $2.74 | 168,463.0000 | 51,200,000 | 0.31% | 0.00% |
| Feb. 21, 2024 | Emergent BioSolutions Inc. | $EBS | LINDAHL RICHARD S | EVP, Chief Financial Officer | D | Common Stock | 4012 | $2.71 | 168,980.0000 | 51,200,000 | 2.32% | 0.01% |
| Feb. 9, 2024 | Compass Therapeutics, Inc. | $CMPX | LINDAHL RICHARD S | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| April 21, 2023 | Compass Therapeutics, Inc. | $CMPX | LINDAHL RICHARD S | Director | A | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 0 | 9999.99% | 0.00% |